ArticleBone marrow transplantation2021
COVID-19 in hematopoietic cell transplant recipients.
Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis.Hematological oncology · 2023Pooled it
- Methodological Considerations on COVID-19 Mortality in Cancer Patients: A Systematic Review and Meta-Analysis.JNCI cancer spectrum · 2022Pooled it
- A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature.Current oncology (Toronto, Ont.) · 2022Pooled it
- Trial
- COVID-19 was associated with the complications after allogeneic hematopoietic stem cell transplantation.Scientific reports · 2024Article
- Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.Frontiers in cellular and infection microbiology · 2023Review
- Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.Frontiers in immunology · 2023Observational
- Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.Frontiers in immunology · 2023Article
- Allogeneic hematopoietic stem cell transplantation in the COVID-19 era.Frontiers in immunology · 2023Review
- COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period.Turkish journal of medical sciences · 2023Article
- COVID-19 and HSCT (Hematopoietic stem cell transplant).Best practice & research. Clinical haematology · 2022Review
- Article
- COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus.Infectious disease clinics of North America · 2022Review
- COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.Blood advances · 2022Article
- Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature.Journal of clinical medicine · 2022Review
- Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update.World journal of stem cells · 2021Review
- The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipientsTurkish journal of medical sciences · 2021Article
- Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2021Article
- Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy.Transplant infectious disease : an official journal of the Transplantation Society · 2021Article
- Pulmonary Complications in Hematopoietic Stem Cell Transplant Recipients-A Clinician Primer.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.